Anika Therapeutics ANIK Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's investing cash flow?
- Anika Therapeutics (ANIK) reported investing cash flow of -$1.24M in Q1 2026.
- How has Anika Therapeutics's investing cash flow changed year-over-year?
- Anika Therapeutics's investing cash flow decreased by 174.1% year-over-year, from $1.67M to -$1.24M.
- What is the long-term trend for Anika Therapeutics's investing cash flow?
- Over 3 years (2021 to 2024), Anika Therapeutics's investing cash flow has grown at a 38.8% compound annual growth rate (CAGR), from -$3.12M to -$8.33M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.